



3<sup>rd</sup> October 2024

## Appointment & resignation of a Director

**SomnoMed Limited (ASX “SOM”, or the Company)**, the leading company in the provision of oral appliance treatment solutions for sleep-related breathing disorders and obstructive sleep apnea (‘OSA’), announces a change in its board composition, with the resignation of Mr Hamish Corlett and the appointment of Mr Benjamin Gisz in his place. Both Mr Corlett and Mr Gisz are Directors of TDM Growth Partners, SomnoMed’s largest shareholder. Mr Corlett has served on the board of SomnoMed since 1<sup>st</sup> May 2018. The change in Directorship is effective from 8<sup>th</sup> October 2024 by way of casual appointment and will be included in the set of resolutions put to shareholders at the upcoming AGM.

Ben is Director and member of the investment team at TDM Growth Partners of TDM Growth Partners, a leading investment firm specializing in long term investments in high growth companies globally.

Ben has extensive investing and financial markets experience, including prior roles in private equity and investment banking with Investec Group and Credit Suisse.

Ben is a current Non-Executive Director at Australian pet supplies ecommerce business Pet Circle, and previously served as a Non-Executive Director on the board of ASX listed dental group Pacific Smiles Limited.

Ben holds a Bachelor of Commerce (Finance and Accounting) from the University of Sydney.

Commenting on the change, SomnoMed Chairman, Mr Guy Russo said, “We thank Hamish for his outstanding service to SomnoMed over the past six years and we are grateful for ongoing representation of TDM Growth Partners on our board via the appointment of Ben.”

---ends---

This release has been approved by the Board of SomnoMed Limited.

### **For further information please contact**

Investor Relations: [ir@somnomed.com](mailto:ir@somnomed.com)

SomnoMed Limited - 20 Clarke St, Crows Nest, NSW, Australia 2065

### **About SomnoMed**

SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialised on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent<sup>®</sup> becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 910,000 patients in over 20 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>